Peer-influenced content. Sources you trust. No registration required. This is HCN.

Eyewire+FDA Approves Apellis’ Syfovre (Pegcetacoplan), First and Only Treatment for Geographic Atrophy

The every-other-month intra-ocular injection shows a reduction in lesion growth that increases over time. The ocular formulation of the drug, previously approved for paroxysmal nocturnal hemoglobinuria, should be available in specialty pharmacies in March 2023.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form